» Articles » PMID: 38743422

Exploring Anabolic Androgenic Steroid Use Among Cisgender Gay, Bisexual, and Queer Men

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2024 May 14
PMID 38743422
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Anabolic androgenic steroids (AAS) are disproportionately used by sexual minority men, with the physical and mental health implications of AAS use incompletely understood.

Objective: To understand the reasons for use and health care needs of gay, bisexual, and queer cisgender men using AAS.

Design, Setting, And Participants: This qualitative study was conducted from November 2021 to May 2023 using self-administered questionnaires and semistructured interviews that were transcribed and coded using reflexive thematic analysis. Participants were recruited through convenience and snowball sampling from lesbian, gay, bisexual, transgender, and queer clinical centers in New York, New York, as well as through online platforms. All patients self-identified as cisgender and gay, bisexual, or queer.

Exposures: History of nonprescribed AAS use for a minimum of 8 consecutive weeks was required.

Main Outcomes And Measures: The primary outcomes were reasons for and health implications of AAS use and interactions with health care practitioners, as determined through interviews. Interview transcripts were collected and analyzed.

Results: Thematic saturation was reached after interviews with 12 male participants (mean [SD] age, 44 [11] years), with the majority of participants identifying as gay (10 participants [83%]), White non-Hispanic (9 participants [75%]), being in their 30s and 40s (9 participants [75%]), holding a bachelor's degree or higher (11 participants [92%]), and having used steroids for a mean (SD) of 7.5 (7.1) years. One participant (8%) self-identified as Black, and 2 (17%) identified as Hispanic. Seven men (58%) met the criteria for muscle dysmorphia on screening. Nine overarching themes were found, including internal and external motivators for initial use, continued use because of effectiveness or fear of losses, intensive personal research, physical and emotional harms experienced from use, using community-based harm reduction techniques, frustration with interactions with the medical community focused on AAS cessation, and concerns around the illegality of AAS.

Conclusions And Relevance: In this qualitative study, AAS use among cisgender gay, bisexual, and queer men was found to be associated with multifactorial motivators, including a likely AAS use disorder and muscle dysmorphia. Despite all participants experiencing harms from use, men seeking medical help found insufficient support with practitioners insistent on AAS cessation and, thus, developed their own harm reduction techniques. Further research is needed to assess the utility of practitioner education efforts, the safety and efficacy of community-developed harm reduction methods, and the impact of AAS decriminalization on health care outcomes for this patient population.

Citing Articles

Harm reduction techniques among cisgender gay, bisexual, and queer men using anabolic androgenic steroids: a qualitative study.

Kutscher E, Arshed A, Greene R, Kladney M Harm Reduct J. 2024; 21(1):196.

PMID: 39523302 PMC: 11552109. DOI: 10.1186/s12954-024-01121-8.

References
1.
Piatkowski T, Neumann D, Dunn M . 'My mind pretty much went to mush': A qualitative exploration of trenbolone in the performance and image enhancing drug community. Drug Alcohol Rev. 2023; 42(6):1566-1576. DOI: 10.1111/dar.13656. View

2.
Kanayama G, Brower K, Wood R, Hudson J, Pope Jr H . Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. Drug Alcohol Depend. 2010; 109(1-3):6-13. PMC: 2875348. DOI: 10.1016/j.drugalcdep.2010.01.011. View

3.
Traish A, Hackett G, Miner M, Morgentaler A . Cardiovascular and Cerebrovascular Safety of Testosterone Therapy. Am J Med. 2019; 132(10):e748. DOI: 10.1016/j.amjmed.2019.04.042. View

4.
Larance B, Degenhardt L, Copeland J, Dillon P . Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug Alcohol Rev. 2008; 27(6):679-86. DOI: 10.1080/09595230802392568. View

5.
Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B . Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018; 52(4):1893-1907. PMC: 5993836. DOI: 10.1007/s11135-017-0574-8. View